Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,893 | 2 | 86.6% |
| Food and Beverage | $293.51 | 4 | 13.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $1,893 | 2 | $0 (2018) |
| Boston Scientific Corporation | $110.24 | 1 | $0 (2024) |
| TELA Bio, Inc. | $96.32 | 1 | $0 (2019) |
| LeMaitre Vascular, Inc. | $74.86 | 1 | $0 (2019) |
| Celgene Corporation | $12.09 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110.24 | 1 | Boston Scientific Corporation ($110.24) |
| 2019 | $171.18 | 2 | TELA Bio, Inc. ($96.32) |
| 2018 | $1,501 | 1 | F. Hoffmann-La Roche AG ($1,501) |
| 2017 | $403.88 | 2 | F. Hoffmann-La Roche AG ($391.79) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/26/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $110.24 | General |
| Category: General - Embolics_PI | ||||||
| 03/26/2019 | LeMaitre Vascular, Inc. | TRIVEX (Device) | Food and Beverage | Cash or cash equivalent | $74.86 | General |
| Category: TRIVEX | ||||||
| 03/06/2019 | TELA Bio, Inc. | Ovitex (Device) | Food and Beverage | In-kind items and services | $96.32 | General |
| Category: Surgical Mesh | ||||||
| 12/31/2018 | F. Hoffmann-La Roche AG | Avastin (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,500.71 | General |
| Category: BioOncology | ||||||
| 10/17/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $12.09 | General |
| Category: Oncology | ||||||
| 03/31/2017 | F. Hoffmann-La Roche AG | Avastin (Biological), Xeloda | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $391.79 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 49 | 1,842 | 93,361 | $5.0M | $1.3M |
| 2022 | 40 | 1,434 | 71,503 | $4.3M | $1.2M |
| 2021 | 32 | 1,032 | 33,167 | $2.1M | $577,018 |
| 2020 | 34 | 1,078 | 24,333 | $2.7M | $747,880 |
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 21,040 | $1.4M | $497,211 | 36.5% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 9,000 | $1.1M | $388,115 | 36.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 4,740 | $259,440 | $86,211 | 33.2% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,430 | $257,400 | $54,684 | 21.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 187 | 448 | $266,148 | $44,630 | 16.8% |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2023 | 24 | 141 | $247,737 | $40,957 | 16.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 20 | 372 | $429,660 | $30,011 | 7.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 250 | $59,000 | $24,508 | 41.5% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 32 | 91 | $84,331 | $11,358 | 13.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 130 | $19,630 | $8,347 | 42.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 9,000 | $36,000 | $7,782 | 21.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 102 | 299 | $60,685 | $6,769 | 11.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 106 | 384 | $54,684 | $4,657 | 8.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $13,500 | $4,525 | 33.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 36 | 85 | $23,545 | $4,247 | 18.0% |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | Office | 2023 | 15 | 27 | $10,881 | $4,107 | 37.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 28 | $9,744 | $3,758 | 38.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 50 | 71 | $15,975 | $3,387 | 21.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 24 | $10,728 | $2,478 | 23.1% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 46 | 17,250 | $86,250 | $2,127 | 2.5% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 12 | 5,900 | $76,700 | $2,091 | 2.7% |
| J9171 | Injection, docetaxel, 1 mg | Office | 2023 | 18 | 3,258 | $110,772 | $1,792 | 1.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 86 | 162 | $11,178 | $1,696 | 15.2% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 35 | 888 | $25,752 | $1,651 | 6.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 51 | 64 | $13,696 | $1,636 | 11.9% |
About Dr. Benjamin Tan, MD
Dr. Benjamin Tan, MD is a Medical Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275551814.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Tan, MD has received a total of $2,186 in payments from pharmaceutical and medical device companies, with $110.24 received in 2024. These payments were reported across 6 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1,893).
As a Medicare-enrolled provider, Tan has provided services to 5,386 Medicare beneficiaries, totaling 222,364 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Practice Information
- Specialty Medical Oncology
- Location Saint Louis, MO
- Active Since 07/18/2006
- Last Updated 04/17/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1275551814
Products in Payments
- Avastin (Biological) $1,893
- Ovitex (Device) $96.32
- TRIVEX (Device) $74.86
- Abraxane (Drug) $12.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Saint Louis
Dr. Brad Kahl, Md, MD
Medical Oncology — Payments: $379,829
Dr. Russell Pachynski, Md, MD
Medical Oncology — Payments: $362,594
Dr. Mark Schroeder, Md, MD
Medical Oncology — Payments: $337,205
Dr. Ravi Vij, Md, MD
Medical Oncology — Payments: $262,216
Dr. Douglas Adkins, Md, MD
Medical Oncology — Payments: $166,184
Dr. Camille Abboud, Md, MD
Medical Oncology — Payments: $155,687